Skip to main content
Equibles
ENTX logo

ENTX · Entera Bio Ltd.

Track ENTX — free

Use ENTX with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about ENTX

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$3.11 +0.22 (+7.61%) At close · Aug 19
Going-concern doubt — cleared Aug 7, 2026

The latest filing states the doubt was alleviated.

“Following the closing of the private placement and receipt of the related net proceeds, management concluded that substantial doubt about the Company's ability to continue as a going concern no longer exists.”
View the 10-Q filed Aug 7, 2026
Market Cap
$524.62M
Shares
173.14M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$3.11 Open$2.93 Day$2.88–3.21 52W close$1.00–3.92 Avg vol 30d3.4M Short int1.2M · 0.7% float · 1.0d Short vol47% Last earningsApr 20, 2026 DataJan 2020–Aug 2026 Filing10-Q · Aug 7

Up next

Next earnings call
May 11, 2028 Est · unconfirmed · in 90 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 7, 2026

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Very Strong Sentiment Neutral Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 14.9 · calm Equity put/call 0.52
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +79%
above
Price vs 50-day avg +47%
above
RSI (14) 64
neutral
MACD trend Negative
52-week position 72%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +53%
trailing
6-month return +106%
trailing
YTD return +60%
this year
Relative strength +94%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow Accumulating
+4% holders QoQ · +7 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
0.66% of float · ▲ +286.7% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
27 holders — near 3-yr high, broad support
Squeeze score 56
elevated · 0–100
Fundamentals
Weak
Revenue growth −77%
Y/Y
Gross margin 0%
contracting
EPS growth 0%
Y/Y
Free cash flow $-7.5M
Balance sheet $7.1M
net cash
Quant / Vol
risk profile
Very High
Volatility 129%
annualized · 1-yr
Max drawdown −68%
past year
ATR 9.1%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
1 · 4 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+79% Bullish
Price vs 50-day avg
+47% Bullish
RSI (14)
64 Neutral
MACD trend
Negative Bearish
52-week position
72% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow Accumulating
+4% holders QoQ · +7 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
0.66% of float · ▲ +286.7% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
27 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $1 Now $3 · 72% Range high $4
vs 200-day avg +79% vs 50-day avg +47%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ENTX
Entera Bio Ltd.
this stock
$524.62M +60.3% -76.8% — 0.7%
ONC
BeOne Medicines Ltd.
 $535.83B +24.0% +22179.2% 823.9 0.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $133.88B +21.8% +46.2% 30.8 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $84.27B +8.9% +20.8% 20.3 3.3%
ARGX
Argenx SE
 $61.75B +22.8% — — 2.1%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
27
% held
6.2%
Net QoQ
+2.9M sh
Top holder
Knoll Capital Management,…
Held Float
View
Short & Settlement
Short Interest Rising
Shares short
1.2M
Days to cover
1.0d
Change
+852.7K sh
View
Short Volume
Short vol %
47%
As of
Aug 19, 2026
Short Total
View
Fails to Deliver
FTD shares
13.6K
Value
$40.2K
As of
Jul 31, 2026
View
Off-Exchange
Off-exchange %
56.7%
Week of
Jul 13, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$42.0K
Net income (FY)
$-11.4M
EPS diluted
$0.25
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 18, 2026
This year
15
View
Exempt Offerings
Offering
$275.0M
Filed
Aug 12, 2026
View
Earnings & Events
Earnings Calls Upcoming
Next call
Oct 12, 2026
Last call
Aug 12, 2026
View
Investor Relations
Upcoming events
1
View

Performance

5D 20D 120D MTD YTD
ENTX +11.1% +53.2% +106.0% +4.0% +60.3%
SPY -0.4% +2.9% +11.6% +3.0% +12.8%
vs SPY +11.5% +50.3% +94.4% +1.1% +47.5%
Key facts CIK 1638097 CUSIP M40527109 13F (30d) 31 filings 30 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)